Taken together, the biomarker kinetics suggest that despite minimal anti-tumor activity, vandetanib and cetuximab may adequately suppress target (EGFR and VEGFR2) activity in metastatic colorectal cancer. The gene discussed is KDR; the disease is metastatic colorectal cancer.